Tianjin Huanhu Hospital

Company snapshot

Tianjin Huanhu Hospital is a pharma organization headquartered in CN. Primary therapeutic focus areas include Neuromyelitis Optica Spectrum Disorders. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 1 (1).

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Tianjin Huanhu Hospital. Not investment advice.

• What is Tianjin Huanhu Hospital?

  Tianjin Huanhu Hospital is a pharma organization headquartered in CN. Primary therapeutic focus areas include Neuromyelitis Optica Spectrum Disorders. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, Clinic

• Is Tianjin Huanhu Hospital publicly traded?

  Tianjin Huanhu Hospital appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Tianjin Huanhu Hospital develop or market?

  No drug profiles are currently linked to Tianjin Huanhu Hospital. Pipeline programs may still list investigational assets.

• What are the latest developments for Tianjin Huanhu Hospital?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Tianjin Huanhu Hospital focus on?

  Tianjin Huanhu Hospital focuses on Neuromyelitis Optica Spectrum Disorders based on our analysis of their pipeline programs and drug development activities.